1. Clinical Overview of CJC-1295 (No DAC)
Molecule: Modified Growth Hormone Releasing Hormone (GHRH) analog
Sequence derivative: tetrasubstituted GHRH (1-29)
Classification:
- Growth Hormone Releasing Hormone (GHRH) analog
- Potent stimulator of GH pulses
- Very short half-life (≈30 minutes)
- Requires frequent timed dosing
- Ideal for pairing with GHRPs (e.g., Ipamorelin)
Difference from DAC version
- CJC-1295 with DAC: long half-life (1–2 weeks), continuous GH elevation
- CJC-1295 (No DAC): short-acting, supports natural pulsatile GH release
Why clinicians prefer No DAC
- Mimics natural physiology
- Less risk of GH "flattening" or desensitization
- Better for body composition
- Better synergy with GHRPs
- Lower fluid retention and fewer metabolic side effects
2. Mechanisms of Action
CJC-1295 (No DAC) enhances natural GH pulses through multiple pathways.
2.1 GHRH Receptor Activation
- Binds pituitary GHRH receptors
- Amplifies endogenous GH pulses
- Enhances downstream IGF-1 production
- Supports circadian GH peaks (nighttime)
2.2 Synergy With Ghrelin Mimetics (GHRPs)
When combined with Ipamorelin, GHRP-2, or GHRP-6, the two peptides amplify each other's effects:
- GHRH analog + GHRP = maximum GH pulse amplitude
- Increased IGF-1
- Enhanced fat-loss
- Improved recovery
2.3 Metabolic & Longevity Effects
GH/IGF-1 axis activation via CJC-1295 supports:
- Lipolysis
- Muscle growth
- Tissue repair
- Cognitive support
- Skin collagen density
- Bone turnover and density
- Sleep depth and recovery
2.4 Sleep Architecture Normalization
Nighttime GH peaks improve:
- Slow-wave sleep
- Nighttime cellular repair
- Circadian rhythm stability
3. Evidence Summary — Clinical Domains of Interest
3.1 Body Composition & Fat Loss
Benefits include:
- Increased lipolysis
- Increased metabolic rate
- Reduction in visceral fat
- Lean muscle preservation
Highly effective when paired with Ipamorelin, SLU-PP-332, 1-Amino-1MQ, MOTS-c.
3.2 Muscle, Joint & Injury Recovery
GH stimulates:
- Protein synthesis
- Muscle fiber repair
- Collagen production
- Soft-tissue healing
Ideal combination with BPC-157, TB-500, RECOVER™.
3.3 Sleep Optimization
CJC-1295 improves:
- Deep sleep cycles
- Sleep duration
- Nighttime GH secretion
Useful for stress-related insomnia, hormonal sleep decline, and aging populations.
3.4 Longevity & Anti-Aging
GH decline accelerates aging. CJC-1295 slows this by:
- Enhancing cellular repair
- Increasing collagen density
- Supporting bone turnover
- Improving immune function
3.5 Hormone Optimization (Adjunct)
Supports:
- Thyroid efficiency
- Androgen balance
- Menopause and andropause support
4. Administration Routes & Clinical Protocols
Administered subcutaneously.
4.1 Standard Dosing Protocol (SC)
- 100–200 mcg SC, 1–3× daily
- Ideally 1 dose pre-bed
- 200 mcg SC, 2× daily — AM (fasted) + PM (pre-bed)
- 200–300 mcg SC, 2–3× daily
Timing Rules
- Inject on an empty stomach
- Avoid eating 30 min before & after
- Combine with Ipamorelin simultaneously for maximal GH pulse
4.2 Cycle Duration
- Standard: 8–12 weeks
- Advanced: 16–24 weeks
- Maintenance: 5 days on / 2 days off
4.3 Most Common Clinical Combination: CJC-1295 (No DAC) + Ipamorelin
- CJC-1295 (No DAC): 100–200 mcg SC
- Ipamorelin: 200–300 mcg SC
- Inject together for synergy
| CJC-1295 (No DAC) | Ipamorelin |
|---|---|
| Stimulates GHRH receptors | Stimulates ghrelin/GHSR receptors |
| Promotes natural GH pulses | Increases amplitude of GH pulses |
| Improves sleep & recovery | Enhances metabolism & repair |
5. Combination Therapy (Peptide Protocol Portal Integration)
5.1 CJC-1295 + Ipamorelin + 1-Amino-1MQ
- GH + metabolic acceleration
- Strong body-recomposition synergy
5.2 CJC-1295 + SLU-PP-332 + MOTS-c
- Maximum metabolic + performance results
- Excellent for stubborn fat or metabolic resistance
5.3 CJC-1295 + BPC-157 + TB-500
- For injury recovery
- Musculoskeletal repair + GH support
5.4 CJC-1295 + NAD+ + SS-31
- Bioenergetic & mitochondrial synergy
- Anti-aging protocols
5.5 CJC-1295 + Epitalon + DSIP
- Powerful circadian normalization
- GH pulse alignment with melatonin & sleep architecture
6. Clinical Decision Trees
Decision Tree 1 — Is CJC-1295 (No DAC) indicated?
Is the goal improved recovery, GH support, or body composition? → YES → Use CJC-1295 No DAC
Is the goal fat loss or stubborn body fat? → YES → CJC + Ipamorelin recommended
Is insomnia or circadian dysfunction present? → YES → Consider nighttime dosing
Is rapid muscle recovery needed? → YES → Combine with BPC-157 / TB-500
Is long-term anti-aging desired? → YES → Combine with Epitalon + NAD+
Decision Tree 2 — Dosing Strategy
Goal: Recovery or sleep? → 100–200 mcg SC pre-bed
Goal: Body recomposition? → 200 mcg SC AM + PM
Goal: Performance? → Combine with Ipamorelin BID
Goal: Longevity? → 100–200 mcg nightly + Epitalon quarterly
7. Integrated Treatment Archetypes
Archetype A — Body Recomposition Protocol
Systemic:
- CJC-1295: 200 mcg AM + PM
- Ipamorelin 300 mcg AM + PM
- SLU-PP-332
- 1-MQ
Archetype B — Injury & Recovery Protocol
Systemic:
- CJC-1295 pre-bed
- Ipamorelin nighttime
- BPC-157 daily
- TB-500 weekly
Archetype C — Anti-Aging & Longevity Protocol
Systemic:
- CJC-1295 nightly
- Epitalon quarterly
- NAD+ weekly
- MOTS-c weekly
- REVIVE™ daily
Archetype D — Sleep, Stress & CNS Repair
Systemic:
- CJC-1295 pre-bed
- DSIP nightly
- REBALANCE™ PM
8. Expected Clinical Timeline
9. Contraindications & Precautions
Absolute Contraindications
- Active cancer (GH-sensitive)
- Pregnancy
- Lactation
Relative Contraindications
- Uncontrolled diabetes
- Severe cardiovascular disease
- Active proliferative retinopathy
10. Adverse Effects
Generally mild:
- Water retention (rare)
- Flushing
- Nausea
- Tingling
- Injection site irritation
Much fewer side effects than GHRP-2 or GHRP-6.
11. Monitoring
- IGF-1 (baseline + 8–12 weeks)
- Fasting glucose / insulin
- Lipids
- Thyroid panel
- Sleep & recovery markers
- Body composition
Legal Disclaimer
The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.
CJC-1295 (No DAC), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.
Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.
Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.
By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.
Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.
References — CJC-1295 (No DAC) Clinical Protocol Guide
Provider Access Required
Create a provider account to read the full clinical guide for CJC-1295 (No DAC).